MSBMesoblast Limited

MSB Stock Price, Valuation & Chart | Mesoblast Limited

Compare

$1.990+0.05 (+2.58%)

At close · 16 Oct 2026, 05:10 am

Sector: Healthcare Industry: Biotechnology Website

Overview Financials Dividends Ratios

MSB Historical price chart

MSB Key Stats

Market Capitalization2.58B

PE Ratio-29.92

EPS-0.07

Trading Volume14.72M

Today's High/Low2.02/1.74

Dividend Yield0.00

52 Week High/Low3.31/1.74

Shares Outstanding1.30B

MSB Financial Statement

MSB Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 6 analysts giving stock ratings to MSB in the past 3 months.

MSB Analysis & performance metrics

MSB Company profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company…

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on…

MSB Management team

Name

Position

Paul J. Simmons BSc, Ph.D.CEO

Scientific Advisor to the Chief Executive Officer

Niva Sivakumar B.Com., L.L.B.

Joint Company Secretary

Fiona See Ph.D.

Senior Vice President & Head of Translational Research

Andrew Chaponnel B.Com.

Interim Chief Finance Officer

Geraldine Storton B.Sc., M.B.A., MMS

Head of Regulatory Affairs & Quality Management

Marcelo Santoro

Chief Commercial Officer

Justin Horst B.S.

Head of Manufacturing

Peter T. Howard B.Sc., L.L.B., LLB (Hons)

General Counsel & Corporate Executive

Name

Position

Paul J. Simmons BSc, Ph.D.CEO

Scientific Advisor to the Chief Executive Officer

Niva Sivakumar B.Com., L.L.B.

Joint Company Secretary

Fiona See Ph.D.

Senior Vice President & Head of Translational Research

Andrew Chaponnel B.Com.

Interim Chief Finance Officer

Geraldine Storton B.Sc., M.B.A., MMS

Head of Regulatory Affairs & Quality Management

Marcelo Santoro

Chief Commercial Officer

Justin Horst B.S.

Head of Manufacturing

Peter T. Howard B.Sc., L.L.B., LLB (Hons)

General Counsel & Corporate Executive

Management Team

Paul J. Simmons BSc, Ph.D.CEO

Scientific Advisor to the Chief Executive Officer

Niva Sivakumar B.Com., L.L.B.

Joint Company Secretary

Fiona See Ph.D.

Senior Vice President & Head of Translational Research

Andrew Chaponnel B.Com.

Interim Chief Finance Officer

Geraldine Storton B.Sc., M.B.A., MMS

Head of Regulatory Affairs & Quality Management

Marcelo Santoro

Chief Commercial Officer

Justin Horst B.S.

Head of Manufacturing

Peter T. Howard B.Sc., L.L.B., LLB (Hons)

General Counsel & Corporate Executive

Management

Paul J. Simmons BSc, Ph.D.CEO

Scientific Advisor to the Chief Executive Officer

Niva Sivakumar B.Com., L.L.B.

Joint Company Secretary

Fiona See Ph.D.

Senior Vice President & Head of Translational Research

Andrew Chaponnel B.Com.

Interim Chief Finance Officer

Geraldine Storton B.Sc., M.B.A., MMS

Head of Regulatory Affairs & Quality Management

Marcelo Santoro

Chief Commercial Officer

Justin Horst B.S.

Head of Manufacturing

Peter T. Howard B.Sc., L.L.B., LLB (Hons)

General Counsel & Corporate Executive

Total 8 executives

MSB Frequently asked questions

What is Mesoblast Limited (MSB) Stock Price?

Current stock price of Mesoblast Limited (MSB) stock is $1.990. The stock price is +2.58% higher in the session. The intraday range can be seen from this page. Volume of Mesoblast Limited (MSB) stock is 14.72M.

Last updated at 16 Oct 2026, 05:10 am.

Why is the Mesoblast Limited (MSB) stock price going up or down today?

The stock price of Mesoblast Limited (MSB) can change with earnings, company news, and overall market sentiment. Mesoblast Limited operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Mesoblast Limited stock expensive at its current price?

Whether Mesoblast Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MSB on this page is -29.92. EPS on this page is -0.07. Compare those figures with peers and growth expectations before deciding if the current Mesoblast Limited price is justified.

How has the stock price of Mesoblast Limited (MSB) performed historically?

Historical performance for Mesoblast Limited (MSB) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MSB reacted to past earnings and market events.

Should I buy Mesoblast Limited (MSB) stock, at this price?

Buying Mesoblast Limited (MSB) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.